TCM-therapy in a Case of Recurrent Hepatocellular Carcinoma with Multiple Radiotherapy

CHEN Mingjun; ZHOU Jing; TONG Zhanqi

Suggestions

您当前的位置：

首页 >

文章列表页 >

TCM-therapy in a Case of Recurrent Hepatocellular Carcinoma with Multiple Radiotherapy

Previous: A Case of Professor ZHOU Yabin's Treatment of Angina Pectoris Combined with Aplastic Anemia

Next: A Case Report of YE Ling Treating Type II Ⅲ Rectal Prolapse

TCM-therapy in a Case of Recurrent Hepatocellular Carcinoma with Multiple Radiotherapy
1.Department of Traditional Chinese Medicine, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100039, China.
2.Chinese PLA Medical School, Beijing, China.
DOI：

扫描看全文

CHEN Mingjun, ZHOU Jing, TONG Zhanqi. TCM-therapy in a Case of Recurrent Hepatocellular Carcinoma with Multiple Radiotherapy[DB/OL].（2023-10-31）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43394610&Fpath=home&index=0
DOI：

CHEN Mingjun, ZHOU Jing, TONG Zhanqi. TCM-therapy in a Case of Recurrent Hepatocellular Carcinoma with Multiple Radiotherapy[DB/OL].（2023-10-31）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=43394610&Fpath=home&index=0 DOI：

摘要

病史摘要,2,患者王某，男性，66岁，主因“肝细胞癌多次射频消融术后，体检提示复发”就诊。患者于2016年7月在解放军总医院腹部B超肝右叶被膜下低回声结构3.7 cm×2.9 cm，2018年8月再次复查腹部B超报告该处边界不清，略向肝外突出，建议定期复查。诉平日心烦急躁，易疲乏，纳欠佳，口干苦，刻下，舌淡红苔薄白，脉沉弦。中医诊断　肝积（肝郁脾虚毒瘀证）西医诊断　复发性肝细胞癌；局部射频消融术后干预措施　中药治以益气健脾、疏肝解郁、解毒散结为法，治疗该患者术后5年余。疗效转归　患者坚持口服中药治疗3年余后，诉心烦、疲乏症状渐而消失，肝右叶低回声区缩小至0.8 cm×1.0 cm，腹部增强MRI无异常，随诊至今已术后生存63个月。

Abstract

Summary of case history,　Wang, 66-year-old male patient, went to the PLAGH hospital for "recurrent hepatocellular carcinoma after multiple radiofrequency ablation". In February 2018, the patient underwent abdominal B-mode ultrasound in PLA General Hospital with a hypoechoic structure of 3.7 cm×2.9 cm under the right hepatic lobe capsule. In August 2018, the abdominal B-mode ultrasound again reported that the boundary was unclear and protruded slightly extrahepatic. Complaint on weekdays upset and impatient, easy fatigue, poor, dry mouth bitter, and pale red tongue moss thin white, heavy pulse.,TCM diagnosis,　liver accumulation (liver stagnation and spleen deficiency),Western medicine diagnosis,　recurrent hepatocellular carcinoma; after local radiofrequency ablation,Intervention measures,　Traditional Chinese medicine was employed to nourish Qi and Spleen, dredging Liver and relieving depression. The patient was treated for more than 5 years after operation.,Clinical outcomes,　The patient persisted in traditional Chinese medicine treatment for more than 3 years, the symptoms of upset and fatigue disappeared, and the right lobe of the liver echocardiogram area narrowed to 0.8×1.0 cm, abdominal enhanced MRI without abnormal, followed up so far has survived 63 months.

关键词

肝细胞癌局部射频消融术后中医药

Keywords

hepatocellular carcinomalocal radiofrequency ablationtraditional Chinese medicine

references

龙江,高宠.原发性肝癌微创消融联合中医诊疗专家共识[J].中华介入放射学电子杂志,2021,9(1):9-19.

王维虎,曾昭冲.中国原发性肝细胞癌放射治疗指南(2020年版)[J].临床肝胆病杂志,2021,37(5):1029-1033.

Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis[J]. Ann Surg, 2015,261(5):947-955.

Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma[J]. Hepatology, 1997,25(1):87-92.

Wang M, Ye Q, Mao D, et al. Research Progress in Liver-Regenerating Microenvironment and DNA Methylation in Hepatocellular Carcinoma: The Role of Traditional Chinese Medicine[J]. Med Sci Monit, 2020,7(26):e920310.

Lee SK, Lee SW, Jang JW, et al. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma[J]. Int J Mol Sci, 2021,22(19):10271.

王姗,吴庆旺,李小科,等.«原发性肝癌诊疗规范(2019年版)»解读[J].临床肝胆病杂志,2020,36(5):996-999.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet. 2018,391(10127):1301-1314.

Rhim H, Lim HK. Radiofrequency ablation of hepatocellular carcinoma: pros and cons[J]. Gut Liver. 2010,Suppl 1(Suppl 1):S113-118.

Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy[J]. Int J Mol Sci, 2020,21(18):6757.

Brown ZJ, Greten TF, Heinrich B. Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy[J]. Hepatology, 2019,70(4):1437-1442.

Sahin IH, Khalil L, Millett R, Kaseb A. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook[J]. Chin Clin Oncol. 2021 Feb;10(1):7.

Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies[J]. Hepatology, 2009,49(2):453-459.

Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation[J]. Radiology, 2005,234(3):961-967.

Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma[J]. Gastroenterology, 2005,129(1):122-130.

Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations[J]. J Hepatol, 2018,68(4):783-797.

Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis[J]. Radiology, 2014,270(3):900-999.

Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma[J]. Cancer, 2000,88(5):1016-1024.

Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma[J]. J Hepatol, 2009,51(5): 890-897.

Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial[J]. Ann Surg, 2015, 261(1): 56-66.

Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases[J]. Dig Surg, 2006, 23(4): 235-240.

Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198(3): 313-318.

Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9): 2074-2081.

Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11): 2006-2016.

ZHAI Xiaofeng,CHEN zhe,LI bai,et al.Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial[J].J Integr Med,2013,11(2):90-100.

Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features[J]. Hepatology. 2016 Dec;64(6):2038-2046.

Boni C, Barili V, Acerbi G, et al. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications[J]. Int J Mol Sci, 2019,20(11):2754.

Wu GL, Zhang L, Li TY, et al. Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression[J]. Chin J Integr Med, 2010,16(2):109-113.

Gong Y. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine[J]. Chin J Integr Med, 2012,18(4):245-9.

Zheng Z, Cho WC, Xu L, et al. Lessons learnt from evidence-based approach of using chinese herbal medicines in liver cancer[J]. Evid Based Complement Alternat Med, 2013,2013:656351.

Anon.Experimental study on the effect of kang-lai-te induced apoptosis of human hepatoma carcinoma cell hepg2[J].Hepatobiliary & Pancreatic Diseases International,2009,8(3):267-272.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Syndrome Differentiation and Treatment of COVID-19 by Academician Tong Xiaolin:Origin, Innovation, and Development of "Cold-Dampness Plague" Theory

Experience on Discussion and Analysis on Application of Cancer Toxicology Theory

Identification and Treatment of Paroxysmal Atrial Fibrillation from Mutual Fanning of Liver Wind and Heart Fire

Seven Proved Cases of Mania

Professor ZHOU Caiyun's Clinical Experience in Stage Syndrome Differentiation Treatment of Behcet's Disease

Related Author

No data

Related Institution

Northeast International Hospital

Human Phenome Institute, Fudan University

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

The Third Affiliated Hospital of Zunyi Medical University

Beijing University of Chinese Medicine

⁰